CA3002661C - Use of gene expression profiling to predict survival in cancer patient - Google Patents

Use of gene expression profiling to predict survival in cancer patient Download PDF

Info

Publication number
CA3002661C
CA3002661C CA3002661A CA3002661A CA3002661C CA 3002661 C CA3002661 C CA 3002661C CA 3002661 A CA3002661 A CA 3002661A CA 3002661 A CA3002661 A CA 3002661A CA 3002661 C CA3002661 C CA 3002661C
Authority
CA
Canada
Prior art keywords
gene
copy number
patient
expression
cks1b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3002661A
Other languages
English (en)
French (fr)
Other versions
CA3002661A1 (en
Inventor
John D. Shaughnessy
Fenghuang Zhan
Bart Barlogie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas
Original Assignee
University of Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arkansas filed Critical University of Arkansas
Priority to CA3142853A priority Critical patent/CA3142853A1/en
Publication of CA3002661A1 publication Critical patent/CA3002661A1/en
Application granted granted Critical
Publication of CA3002661C publication Critical patent/CA3002661C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3002661A 2004-05-21 2005-05-20 Use of gene expression profiling to predict survival in cancer patient Active CA3002661C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3142853A CA3142853A1 (en) 2004-05-21 2005-05-20 Use of gene expression profiling to predict survival in cancer patient

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57366904P 2004-05-21 2004-05-21
US60/573,669 2004-05-21
US60631904P 2004-09-01 2004-09-01
US60/606,319 2004-09-01
CA2567350A CA2567350C (en) 2004-05-21 2005-05-20 Use of gene expression profiling to predict survival in cancer patient

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2567350A Division CA2567350C (en) 2004-05-21 2005-05-20 Use of gene expression profiling to predict survival in cancer patient

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3142853A Division CA3142853A1 (en) 2004-05-21 2005-05-20 Use of gene expression profiling to predict survival in cancer patient

Publications (2)

Publication Number Publication Date
CA3002661A1 CA3002661A1 (en) 2005-12-08
CA3002661C true CA3002661C (en) 2022-03-15

Family

ID=35451480

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3002661A Active CA3002661C (en) 2004-05-21 2005-05-20 Use of gene expression profiling to predict survival in cancer patient
CA2567350A Active CA2567350C (en) 2004-05-21 2005-05-20 Use of gene expression profiling to predict survival in cancer patient
CA3142853A Pending CA3142853A1 (en) 2004-05-21 2005-05-20 Use of gene expression profiling to predict survival in cancer patient

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2567350A Active CA2567350C (en) 2004-05-21 2005-05-20 Use of gene expression profiling to predict survival in cancer patient
CA3142853A Pending CA3142853A1 (en) 2004-05-21 2005-05-20 Use of gene expression profiling to predict survival in cancer patient

Country Status (6)

Country Link
US (4) US8843320B2 (es)
EP (2) EP2537942B1 (es)
CA (3) CA3002661C (es)
DK (1) DK2537942T3 (es)
ES (1) ES2555994T3 (es)
WO (1) WO2005116259A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2555994T3 (es) 2004-05-21 2016-01-12 The Board Of Trustees Of The University Of Arkansas System Uso de perfiles de expresión génica para predecir la supervivencia en un paciente con cáncer
US7914988B1 (en) * 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
KR100893566B1 (ko) * 2006-05-23 2009-04-17 재단법인 목암생명공학연구소 Ｃｋｓ１ｂ ＲＮＡｉ를 함유하는 항암용 조성물
US20090022731A1 (en) * 2006-08-25 2009-01-22 Wyeth Arthritis-associated B cell gene expression
WO2008057545A2 (en) * 2006-11-07 2008-05-15 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of genomic signatures of high-risk multiple myeloma and uses thereof
US20080274911A1 (en) * 2006-11-07 2008-11-06 Burington Bart E Gene expression profiling based identification of genomic signature of high-risk multiple myeloma and uses thereof
US20120129168A1 (en) * 2009-04-10 2012-05-24 Shingo Ichimiya Tumor marker and use thereof
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
KR101389018B1 (ko) 2011-07-19 2014-04-29 연세대학교 산학협력단 담도암 암 줄기세포 특성에 기초한 담도암 신규 바이오마커 및 그의 용도
JP2016525883A (ja) * 2013-05-17 2016-09-01 ナショナル ヘルス リサーチ インスティテュートス 腺癌を予後的に分類及び治療する方法
EP3567123B1 (en) * 2013-05-20 2021-11-10 BioVentures, LLC Gep5 model for multiple myeloma
KR20160033780A (ko) * 2013-08-22 2016-03-28 반다 파마슈티칼즈, 인코퍼레이티드. 다발성 골수종 치료
KR20210127821A (ko) 2013-08-22 2021-10-22 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료
CN103743910B (zh) * 2013-12-27 2015-11-18 上海市计划生育科学研究所 Ctbs蛋白作为精卵结合受体的靶点在筛选精卵结合抑制剂中的应用
US20170107580A1 (en) 2015-10-15 2017-04-20 Dendreon Pharmaceuticals, Inc. Gene expression markers for predicting overall survival in subjects treated with sipuleucel-t
CN106885908B (zh) * 2015-12-23 2019-05-07 中国人民解放军第二军医大学 血清psmd4蛋白的检测试剂盒及其检测方法与应用
US11434301B2 (en) 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
US20190025311A1 (en) * 2017-07-21 2019-01-24 Liquid Biopsy Research LLC Methods for detection of plasma cell dyscrasia
EP3476949A1 (en) 2017-10-31 2019-05-01 Centre National De La Recherche Scientifique Prognosis method of multiple myeloma
WO2021072112A1 (en) * 2019-10-09 2021-04-15 Hdt Bio Corp. Detection of desmoglein-2 in cancers of epithelial origin
CN116419747A (zh) 2020-08-07 2023-07-11 福蒂斯治疗公司 靶向cd46的免疫偶联物及其使用方法
IL278473A (en) * 2020-11-03 2022-06-01 Yeda Res & Dev Methods for diagnosing and determining treatment in multiple myeloma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105149B1 (en) * 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US20030036163A1 (en) * 2001-07-10 2003-02-20 Myriad Genetics, Incorporated Novel PN9826 nucleic acids and use thereof
JP2005137202A (ja) 2001-11-02 2005-06-02 Fujisawa Pharmaceut Co Ltd 多発性骨髄腫の分子診断方法
US8954283B2 (en) 2001-11-07 2015-02-10 John D. Shaughnessy, JR. Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
US7935679B2 (en) * 2001-11-07 2011-05-03 Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of CKS1B as a potential therapeutic target in multiple myeloma
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7348418B2 (en) * 2002-02-08 2008-03-25 Memorial Sloan-Kettering Cancer Center Carcinoma-related genes and polypeptides and methods of use thereof
CA2500472A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
EP1581629B1 (en) 2002-12-06 2015-04-01 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
AU2004271192B2 (en) * 2003-09-03 2011-11-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
US7741035B2 (en) 2004-05-21 2010-06-22 Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
ES2555994T3 (es) 2004-05-21 2016-01-12 The Board Of Trustees Of The University Of Arkansas System Uso de perfiles de expresión génica para predecir la supervivencia en un paciente con cáncer
US20100316629A1 (en) * 2004-09-01 2010-12-16 Shaughnessy Jr John D Use of gene expression profiling to predict survival in cancer patient
WO2008057545A2 (en) 2006-11-07 2008-05-15 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of genomic signatures of high-risk multiple myeloma and uses thereof
EP2390662A1 (en) 2010-05-27 2011-11-30 Erasmus University Medical Center Rotterdam Molecular classification of multiple myeloma
WO2011153545A2 (en) 2010-06-04 2011-12-08 Bioarray Therapeutics, Inc. Gene expression signature as a predictor of chemotherapeutic response in breast cancer
CA2854665A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene expression signatures of neoplasm responsiveness to therapy

Also Published As

Publication number Publication date
US20170342501A1 (en) 2017-11-30
EP1766086A2 (en) 2007-03-28
CA2567350A1 (en) 2005-12-08
US20200291486A1 (en) 2020-09-17
CA3002661A1 (en) 2005-12-08
CA2567350C (en) 2018-06-12
EP1766086A4 (en) 2009-10-28
WO2005116259A3 (en) 2009-04-02
US20130338025A1 (en) 2013-12-19
DK2537942T3 (en) 2015-12-14
US20050260664A1 (en) 2005-11-24
CA3142853A1 (en) 2005-12-08
ES2555994T3 (es) 2016-01-12
EP2537942B1 (en) 2015-09-23
US9650677B2 (en) 2017-05-16
EP2537942A1 (en) 2012-12-26
US10597729B2 (en) 2020-03-24
WO2005116259A2 (en) 2005-12-08
US8843320B2 (en) 2014-09-23

Similar Documents

Publication Publication Date Title
US20200291486A1 (en) Use of gene expression profiling to predict survival in cancer patient
US7741035B2 (en) Use of gene expression profiling to predict survival in cancer patient
Yu et al. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor
US20100316629A1 (en) Use of gene expression profiling to predict survival in cancer patient
EP1824997B1 (en) Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment
Ouillette et al. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14
Bernardini et al. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer
US20200270691A1 (en) Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
Rabbani et al. Mutation of cell cycle regulators and their impact on superficial bladder cancer
US20140287422A1 (en) Method for Selecting a Treatment for Non-Small Cell Lung Cancer Using Gene Expression Profiles
US7935679B2 (en) Gene expression profiling based identification of CKS1B as a potential therapeutic target in multiple myeloma
US20120141603A1 (en) Methods and compositions for lung cancer prognosis
Chen et al. Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification
US20160024591A1 (en) Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
WO2013082105A1 (en) Stat3 activation as a marker for classification and prognosis of dlbcl patients
Carless et al. Cytogenetics of primary skin tumors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181018